SLC9A6 and Disorder of lipid metabolism: As shown in Figure S10A–C, pharmacological inhibition of either the ERK or p38 pathway, especially combined inhibition, significantly ameliorated SLC9A6‐126aa‐induced lipid metabolism disorders.